The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: A 1-year prospective randomized study

Nephrology Dialysis Transplantation

Volumn 29, Issue 5, 2014, Pages 1061-1073

  Locatelli, Francesco ^a   Spasovski, Goce ^b   Dimkovic, Nada ^c   Wanner, Christoph ^d   Dellanna, Frank ^e   Pontoriero, Giuseppe ^a  

^a A MANZONI HOSPITAL   (Italy)

^b SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e Gemeinschaftspraxis Karlstrasse   (Germany)

Author keywords

Chronic kidney disease; colestilan; hyperphosphataemia; placebo; sevelamer

Indexed keywords

CALCIUM; CHOLESTEROL; COLESTILAN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; TRIACYLGLYCEROL; URIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; OPEN STUDY; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

CHRONIC KIDNEY DISEASE; COLESTILAN; HYPERPHOSPHATAEMIA; PLACEBO; SEVELAMER;

ADULT; AGED; AGED, 80 AND OVER; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; CALCIUM; CHOLESTEROL; FEMALE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; PHOSPHORUS; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84899117393     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft476     Document Type: Article

References (45)

1. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroid-ism. Nephrol Dial Transplant 1996; 11(Suppl 3): 130-135
2. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
3. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695-701
4. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
5. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113): S1-S130
7. Isakova T, Gutiérrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388-396
8. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60: 90-101
9. Cannata-Andia JB. COSMOS Investigators. The use of phosphate binding agents is associated with lower mortality: results from the COSMOS study. Presented at the 49th ERA-EDTA Congress, May 24-27 2012, Paris, France. Available from: http://www.eraedta2012.org/images/05-Cannata-Andia-Results-from- the-COSMOS-study.pdf
10. Frazão JM, Adragão T. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Nephron Clin Pract 2012; 120: c108-c119
11. Guérin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
12. Hill KM, Martin BR, Wastney ME et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013; 83: 959-966
13. Navaneethan SD, Palmer SC, Vecchio M et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Co-chrane Database Syst Rev 2011; CD006023. doi: 10.1002/14651858
14. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevela-mer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
15. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
16. Toussaint ND, Lau KK, Polkinghorne KR et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton) 2011; 16: 290-298
17. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137
18. Shantouf R, Budoff MJ, Ahmadi N et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialy-sis patients. Am J Nephrol 2008; 28: 275-279
19. Baigent C, Landray MJ, Reith C. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
20. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41(4 Suppl 3): I-IV, S1.-S91
21. Grundy SM, Cleeman JI, Merz CN. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-732
22. Reiner Z, Catapano AL, De Backer G. European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818
23. Kurihara S, Tsuruta Y, Akizawa T. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant 2005; 20: 424-430
24. Locatelli F, Dimkovic N, Spasovski G. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidae-mia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant 2013; 28: 1874-1888
25. Heymann EP, Kassimatis TI, Goldsmith JA. Dyslipidaemia, statins, and CKD patients' outcomes-review of the evidence in the post-sharp era. J Nephrol 2012; 25: 460-472
26. Sturm G, Lamina C, Zitt E et al. Association of HbA1c values with mortality and cardiovascular events in diabetic dialysis patients. The INVOR study and review of the literature. PLoS One 2011; 6: e20093
27. Neri L, Rocca Rey LA, Lentine KL et al. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis 2011; 58: 398-408
28. Suliman ME, Johnson RJ, García-López E et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006; 48: 761-771
29. Locatelli F, Dimkovic N, Pontoriero G et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyper-phosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 2010; 25: 574-581
30. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
31. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
32. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897
33. Moe S, Drüeke T, Cunningham J. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteo-dystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
34. Di Iorio B, Bellasi A, Russo D. INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7: 487-493
35. National Kidney Foundation. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55: 773-799
36. Block GA, Port FK. Re-evaluation of risks associated with hyperphospha-taemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
37. Goldsmith DR, Scott LJ, Cvetkovic RS et al. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs 2008; 68: 85-104
38. Tsimihodimos V, Dounousi E, Siamopoulos C. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008; 28: 958-973
39. Weichhart T, Kopecky C, Kubicek M et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2013; 23: 934-947
40. Reasner CA. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 2008; 52: 136-144
41. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
42. Wen CP, David Cheng TY, Chan HT et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis 2010; 56: 273-288
43. Jalal DI, Chonchol M, Chen W et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis 2013; 61: 134-146
44. Hsu CY, Iribarren C, McCulloch CE et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009; 169: 342-350
45. Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: con-founders, culprits, and circles. Am J Kidney Dis 2010; 56: 247-250